Cytivas

Cytiva, commonly written Cytiva, is a global provider of technologies and services for biopharmaceutical development and manufacturing. The company supplies equipment, consumables, and software used across biotechnology workflows, including upstream and downstream bioprocessing, analytical testing, and cell culture.

History: Cytiva was established in 2020 as a rebranding of GE Life Sciences after the sale of GE's biopharma business to Danaher. The new brand integrated core product lines and customer support to serve the biopharmaceutical industry, aligning legacy GE HealthCare Life Sciences assets under a unified organization.

Products and services: Key offerings include chromatography and purification systems (notably the AKTA family), filtration and bioprocessing consumables, cell culture media and supplements, analytical instruments, sensors, and related software and services. Cytiva supports activities from early-stage discovery through process development and GMP manufacturing, with automation, data management, training, and technical support as part of its services.

Global presence and customers: The company operates in multiple regions through manufacturing sites, distribution partners, and service centers. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, and academic and research institutions.

Strategy and impact: Cytiva focuses on enabling efficient and scalable bioprocessing, investing in digital solutions, interoperability, and sustainability. It pursues collaborations with industry partners to accelerate drug development and production while maintaining safety, quality, and regulatory compliance.